This content is machine translated Chronic myeloid leukemia State of the Art – where are we at CML in 2017? CML patients have a normal life expectancy when treated with Abl-specific kinase inhibitors (TKIs) in chronic phase. Imatinib, dasatinib and nilotinib are approved in the first-line treatment of CML. In…
